Clinical relevance of peripheral vascular occlusive disease in patients with rheumatoid arthritis and systemic lupus erythematosus

Journal of Vascular Surgery

Volumn 38, Issue 1, 2003, Pages 111-115

  Henke, Peter K ^a,b   Sukheepod, Pasu ^a,b   Proctor, Mary C ^a,b   Upchurch Jr , Gilbert R ^a,b   Stanley, James C ^a,b  

^a University of Michigan School of Medicine ^*  (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER;

AGED; ANKLE BRACHIAL INDEX; AORTOFEMORAL BYPASS; ARTICLE; BYPASS SURGERY; CLAUDICATION; CLINICAL ARTICLE; CONTROLLED STUDY; EMBOLECTOMY; FEMALE; HUMAN; LIMB AMPUTATION; LIMB SALVAGE; MALE; MEDICAL RECORD; PAIN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEDIMENTATION RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; METHODOLOGY; PERIPHERAL VASCULAR DISEASE; VASCULAR SURGERY;

AGED; ANTI-INFLAMMATORY AGENTS; ARTERIAL OCCLUSIVE DISEASES; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIMB SALVAGE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PERIPHERAL VASCULAR DISEASES; RETROSPECTIVE STUDIES; VASCULAR SURGICAL PROCEDURES;

EID: 0038108830     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0741-5214(03)00074-0     Document Type: Article

References (30)

1. McDermott MM, Greenland P, Lin K, Guralnik JM, Criqui MH, Dolan NC, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001;286:1599-1606.
2. Ridker PM, Rifai N, Clearfield M, Downs JR, Wies S, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-8.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
6. Ames PRJ. Medical perspective antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: a unifying "membrane stress syndrome" hypothesis. Lupus 1994;3:371-7.
7. Urowitz M, Gladman D, Bruce I. Atherosclerosis and systemic lupus erythematosus. Curr Rheum Report 2000;2:19-23.
8. Thiagarajan P. Atherosclerosis, autoimmunity, and systemic lupus erythematosus. Circulation 2001;104:1876-7.
9. Pasceri V, Yeh ETH. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999;100:2124-6.
10. del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44: 2737-45.
11. Hahn BH. Systemic lupus erythematosus. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al, editors. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill; 1998. p 1874-80.
12. Lipsky PE. Rheumatoid arthritis. In: Fauci AS, Brannwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al, editors. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill; 1998. p 1880-8.
13. Pun YL, Barraclongh DR, Mnirden KD. Leg ulcers in rheumatoid arthritis. Med J Anst 1990;153:585-7.
14. Hafner J, Schneider E, Burg G, Cassina PC. Management of leg ulcers in patients with rheumatoid arthritis or systemic sclerosis: the importance of concomitant arterial and venons disease. J Vasc Surg 2000;32: 322-9.
15. Oien RF, Hakansson A, Hansen BU. Leg ulcers in patients with rheumatoid arthritis: a prospective study of aetiology, wound healing and pain reduction after pinch grafting. Rheumatology 2001;40:816-20.
16. McDonald J, Stewart J, Urowitz MB, Gladman DD. Peripheral vascular disease in patients with systemic lupus erythematosus. Ann Rheum Dis 1992;51:56-60.
17. Wheatley MJ, Hennein HA, Greenfield LJ. Lower extremity arterial disease in systemic lupus erythematosus. Arch Surg 1991;126:109-10.
18. Bakker FC, Rauwerda JA, Moens B, van den Broek TAA. Intermittent claudication and limb threatening ischemia in systemic lupus erythematosus and in SLE-like disease: a report of two cases and review of the literature. Surgery 1989;106:21-5.
19. Allison PD. Survival analysis using the SAS system. Gary, NC: SAS Institute; 1995.
20. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997;26:1-36.
21. Taylor LM, Edwards JM, Porter JM. Present status of reversed vein bypass grafting: five-year results of a modern series. J Vasc Surg 1990;11:193-206.
22. Donaldson MC, Whittemore AD, Mannick JA. Further experience with an all autogenous tissue policy for infraingninal reconstruction. J Vasc Surg 1993;18:41-8.
23. Feinglass J, Pearce WH, Martin GJ, Gibbs J, Cowper D, Sorenson M, et al. Postoperative and amputation-free survival outcomes after femorodistal bypass grafting surgery: findings from the Department of Veteran's Affairs National Surgical Quality Improvement Program. J Vasc Surg 2001;34:283-90.
24. DePalma RG, Moskowitz RW, Holden WD. Peripheral ischemia and collagen disease. Arch Surg 1973;105:313-8.
25. Suzuki T, Kopia G, Shin-ichiro H, Bailey LR, Llanos G, Wilensky R, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-93.
26. Hirko MK, McShannic JR, Schmidt SP, Sharp WV, Evancho MM, Sims RL, et al. Pharmacologic modulation of intimal hyperplasia in canine vein interposition grafts. J Vasc Surg 1993;17:877-87.
27. Carson MJ, Lo D. The push-me pull-yon of T cell activation. Science 2001;293:618-9.
28. Hansson GK. The B cell: a good guy in vascular disease? Arterioscler Thromb Vasc Biol 2002;22:523-4.
29. Shortell CK, Onriel K, Green RM, Condemi JJ, DeWeese JA. Vascular disease in the antiphospholipid syndrome: a comparison with the patient population with atherosclerosis. J Vase Surg 1992;15:158-66.
30. Bacharach JM, Lie JT, Homburger HA. The prevalence of vascular occlusive disease associated with antiphospholipid syndromes. Int Angiol 1992;11:51-6.